OPRX - OptimizeRx Q2 Non-GAAP EPS revenue misses FY22 guidance below consensus
- OptimizeRx press release ( NASDAQ: OPRX ): Q2 Non-GAAP EPS of $0.04 (vs. $0.10 Y/Y) misses by $0.05 .
- Revenue of $14M (+2.9% Y/Y) misses by $3.06M .
- For FY22, net revenue is expected to be in the range of of $62M to $68M (vs. consensus of $81.47M)
For further details see:
OptimizeRx Q2 Non-GAAP EPS, revenue misses, FY22 guidance below consensus